How to convert Novolin (NPH/Regular insulin) 70/30 to Lantus (insulin glargine) dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

To calculate a Lantus dose from Novolin 70/30, consider converting based on individual needs and current glycemic control, with one possible approach being to adjust the dose according to the patient's specific requirements. When converting from Novolin 70/30 to Lantus, it's essential to understand that these are different types of insulin with distinct pharmacokinetic profiles, as noted in the 2023 standards of care in diabetes 1. The conversion should take into account the total daily dose of Novolin 70/30 and the patient's current glycemic control.

  • Key considerations include:
    • The different potency and duration of action between Lantus, a long-acting basal insulin, and Novolin 70/30, a premixed insulin containing both intermediate-acting and short-acting components.
    • The need for a rapid-acting insulin for mealtime coverage, as Lantus only provides basal insulin.
    • Frequent blood glucose monitoring, ideally 4-6 times daily, during the transition to adjust the Lantus dose.
  • The adjustment of the Lantus dose should be based on the patient's response, with increments or decrements made as necessary to achieve target fasting glucose levels, under medical supervision, considering individual insulin sensitivity and other factors like diet, activity level, and concurrent medications, as suggested by the approach to pharmacologic treatment of diabetes 1.
  • It is crucial to monitor the patient closely during this transition and adjust the insulin regimen as needed to minimize the risk of hypoglycemia or hyperglycemia, ensuring the best possible outcome in terms of morbidity, mortality, and quality of life.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Calculating Lantus Dose from Novolin 70/30

To calculate the Lantus dose from Novolin 70/30, consider the following points:

  • Lantus (insulin glargine) is a long-acting basal insulin, whereas Novolin 70/30 is a premixed insulin containing 70% NPH (intermediate-acting) and 30% regular (short-acting) insulin 2.
  • When switching from a premixed insulin to a basal-bolus regimen, the total daily dose of premixed insulin can be used as a starting point for calculating the basal insulin dose 3.
  • A study on transferring patients from self-mixed insulin regimens to a premixed insulin regimen (Novolin 70/30) found that the transfer was often made on a dose-for-dose basis 2.
  • However, when switching to Lantus, the dose may need to be adjusted based on the patient's individual needs and response to the medication.

Key Considerations

  • The patient's current dose of Novolin 70/30 and their blood glucose control should be taken into account when calculating the Lantus dose.
  • The Lantus dose may need to be titrated to achieve optimal blood glucose control, and this can be done based on the patient's fasting blood glucose levels 4, 5.
  • It is essential to monitor the patient's blood glucose levels and adjust the Lantus dose as needed to minimize the risk of hypoglycemia and achieve optimal glycemic control.

Dose Calculation

  • There is no direct formula provided in the available studies for calculating the Lantus dose from Novolin 70/30.
  • However, a general approach would be to start with a dose of Lantus that is equivalent to the patient's current total daily dose of Novolin 70/30, and then adjust the dose based on the patient's response and blood glucose control 3, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.